Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Dig Liver Dis ; 43(9): 736-41, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21616733

ABSTRACT

BACKGROUND: Despite chronic liver diseases represent an important cause of illness in Italy, data from family practice are poor. AIM: To assess the management of chronic liver diseases by general practitioners in a large area of Southern Italy. METHODS: This was a 5-year retrospective analysis from 104 physicians in charge of a population of 143,159 adult subjects. RESULTS: Amongst 6550 patients with chronic liver disease (4.7%, 3400 M, median age 57 years), 1330 (20.3%) had HCV infection, 226 (3.4%) HBV infection, and 293 (4.5%) liver cirrhosis (25 alcohol-related). The prevalence of alcohol consumption, recorded by 90% of physicians, was 20.4%. Hypertransaminasemia and liver steatosis had a prevalence of 6.7% and 2.4%, respectively. Although transaminases were checked 3 times over 5 years in 80% of cases, few patients were investigated for viral infection, and less than 50% underwent ultrasonography and consultation, leaving undefined a consistent number of cases. Alcohol consumption, body mass index and ultrasonography were poorly checked even in hypertransaminasemic patients. CONCLUSIONS: This study shows that data recording by general practitioners in chronic liver disease patients lacks homogeneity and can miss important information. One unmet need is therefore the integration between theoretical knowledge and practice to share similar behaviours and improve the management of these patients.


Subject(s)
Alcohol Drinking/adverse effects , General Practitioners , Liver Diseases/diagnosis , Practice Patterns, Physicians' , Adolescent , Adult , Aged , Aged, 80 and over , Body Mass Index , Chronic Disease , Female , General Practitioners/education , Humans , Italy , Liver Diseases/diagnostic imaging , Liver Diseases/therapy , Liver Diseases/virology , Male , Middle Aged , Retrospective Studies , Transaminases/blood , Ultrasonography , Young Adult
2.
Am J Gastroenterol ; 103(12): 3159-66, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18786125

ABSTRACT

BACKGROUND AND AIMS: A deranged metabolic status and alcohol intake may trigger induction and progression of chronic hepatitis C virus (HCV) liver disease. The aim of this study was to evaluate whether dietary composition affects the severity of liver damage and response to therapy in patients with HCV-related chronic hepatitis. METHODS: We enrolled 1,084 patients with biopsy-proven HCV-related chronic hepatitis (432 treated with interferon plus ribavirin) and 2,326 healthy subjects in this prospective study conducted in a university hospital. Dietary habits were recorded in enrolled individuals, and their alcohol consumption was evaluated with a questionnaire (AUDIT). Body mass index, and plasma levels of blood glucose, nitrogen, creatinine, cholesterol, and triglycerides were also measured. All individuals underwent routine liver tests and HCV genotyping. RESULTS: At study onset, there were no differences in metabolic status or alcohol consumption between patients and controls. About 50% of each group was overweight, and about 60% consumed alcohol. Patients and controls had similar dietary habits. Intake of carbohydrates, lipids and polyunsaturated fatty acids, and alcohol consumption were independent factors of liver damage at histology (logistic regression analysis). Some dietary components (unsaturated fatty acids, iron, zinc, vitamin A, and niacin) and alcohol intake differed significantly (P < 0.05 and P 0.01, respectively; univariate analysis) between responders and nonresponders to interferon therapy. Genotype, age, body mass index, steatosis, and fibrosis were independent predictors of therapy outcome (P < 0.02; multivariate analysis). CONCLUSIONS: The severity of HCV-related chronic hepatitis depends on a variety of factors. Our results show that dietary composition is related to the extent of liver damage. Although traditional risk factors independently affected treatment response, some dietary components were associated with nonresponse to therapy in our patients. This suggests that HCV patients may benefit from instructions regarding their diet.


Subject(s)
Antiviral Agents/therapeutic use , Diet , Hepatitis C, Chronic/complications , Interferons/therapeutic use , Liver Cirrhosis/drug therapy , Adult , Aged , Aged, 80 and over , Alcohol Drinking/adverse effects , Female , Humans , Liver Cirrhosis/etiology , Male , Middle Aged , Prospective Studies , Ribavirin/therapeutic use , Young Adult
3.
Am J Clin Pathol ; 130(1): 34-42, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18550468

ABSTRACT

Paneth cells, granulated epithelial cells located at the base of small bowel crypts, have a crucial role in innate immunity. Because controversies remain concerning Paneth cell numbers and function in celiac disease (CD), we quantified Paneth cells and human alpha-defensin (HD)-5 and HD-6 in 28 patients with uncomplicated CD, 8 patients with complicated CD (3 with ulcerative jejunoileitis, 2 with refractory sprue, and 3 with enteropathy-associated T-cell lymphoma), and 14 control subjects. Paneth cell numbers and proliferation did not differ in uncomplicated untreated and treated CD and control cases. However, the number of Paneth cells was significantly reduced in complicated CD. Mucosal HD-5 and HD-6 were comparable in uncomplicated untreated and treated CD and control cases. Ex vivo gliadin challenge of treated CD biopsy specimens had no effect on mucosal HD-5 and HD-6 transcripts. Paneth cell numbers and alpha-defensins are unchanged in the mucosa in uncomplicated CD. Further studies are needed to clarify the implications of reduction of numbers of Paneth cells in complicated CD.


Subject(s)
Celiac Disease/pathology , Paneth Cells/pathology , Adult , Aged , Cell Proliferation , Duodenum/pathology , Female , Humans , Intestinal Mucosa/pathology , Ki-67 Antigen/analysis , Male , Middle Aged , RNA, Messenger/metabolism , alpha-Defensins/analysis
5.
Clin Cancer Res ; 9(6): 2015-21, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12796363

ABSTRACT

PURPOSE: Helicobacter pylori causes gastric damage and is involved in gastric carcinogenesis. Vascular endothelial growth factor (VEGF) plays a major role in gastric mucosa repair and is overexpressed in gastric cancer. We investigated: (a) whether H. pylori, and in particular H. pylori VacA toxin, affected VEGF expression in gastric epithelial cells in culture; and (b) the signal transduction pathway involved in any effect exerted by H. pylori. EXPERIMENTAL DESIGN: MKN-28 cells were incubated with uninoculated BCF (control) or with BCF obtained from VacA-producing wild-type H. pylori 60190 strain or from its isogenic mutant 60190:v1, specifically lacking vacA gene in the presence or absence of ZD 1839, a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, PD098059, a selective inhibitor of mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase, the kinase responsible for ERK phosphorylation, or SC-236, a selective inhibitor of cyclooxygenase (COX)-2 for 24-48 h. RESULTS: (a) Toxigenic H. pylori up-regulated VEGF mRNA and protein expression and caused a 2.5-fold increase in VEGF release compared with control, whereas nontoxigenic H. pylori did not; (b) H. pylori VacA toxin-induced up-regulation of VEGF was counteracted by selective inhibition of EGFR tyrosine kinase; (c) toxigenic H. pylori activated the ERK/MAP kinase cascade, and inhibition of MAP kinase activation counteracted H. pylori-induced VEGF up-regulation; (d) toxigenic H. pylori up-regulated COX-2 expression, and this effect was counteracted by blockade of EGFR tyrosine kinase; and (e) COX-2 selective inhibition counteracted H. pylori-induced up-regulation of VEGF. CONCLUSION: (a) H. pylori up-regulates VEGF expression in gastric epithelial cells; and (b) this effect is specifically related to VacA toxin and seems to depend on the activation of an EGFR-, MAP kinase-, and COX-2-mediated pathway.


Subject(s)
Bacterial Proteins/physiology , ErbB Receptors/physiology , Helicobacter pylori/pathogenicity , Isoenzymes/physiology , Prostaglandin-Endoperoxide Synthases/physiology , Stomach Neoplasms/metabolism , Stomach Neoplasms/microbiology , Vascular Endothelial Growth Factor A/biosynthesis , Cyclooxygenase 2 , Gefitinib , Humans , MAP Kinase Signaling System/physiology , Membrane Proteins , Quinazolines/pharmacology , RNA, Messenger/analysis , Signal Transduction , Up-Regulation , Vascular Endothelial Growth Factor A/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...